January 6, 2016
LivaNova: “FDA’s Warning Letter can be resolved without material impact on financial results”
LivaNova said that FDA’s Warning Letter can be resolved without a material impact on financial results.
Pharmaceuticals, Biotechnology and Life Sciences
LivaNova said that FDA’s Warning Letter can be resolved without a material impact on financial results.
Glenmark Pharmaceuticals Inc., has been granted tentative approval by the USFDA for its Dronedarone Tablets, 400 mg, the generic version…
Glenmark confirms reaching agreement with Roche over patent disputes
Suven Life Sciences Ltd has announced that the grand of one product patent from Canada, one from ARIPO and one from South Korea corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030.
Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, has entered into a licensing agreement with Emergex Vaccines Limited, a private UK biotechnology company focused on infectious diseases utilising Midatech’s gold nanoparticle technology.
Brooks Laboratories’ new manufacturing unit in Vadodra to kick off production in 3 months
India’s Dr. Reddy’s has re-launched its Esomeprazole Magnesium Delayed-Release Capsules, which is a therapeutic equivalent generic version of Nexium Delayed-Release…
Midatech Pharma, the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, has…
Anavex had cash and cash equivalents of $15.3 million as of September 30, 2015, compared with $7.3 million as at…
Suven Life Sciences Ltd (SUVEN) has got the grant of one product patent from Europe and one product patent from Macau corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029.